Urinary Tract Biopsy Correlates Urothelial Carcinoma Diagnosis
By LabMedica International staff writers Posted on 28 Sep 2017 |

Image: Histopathology of transitional carcinoma of the urinary bladder from a transurethral biopsy. This exophytic papillary tumor shows multiple finger-like projections lined by multiple layers of urothelium (transitional epithelium) (Photo courtesy of Pathpedia).
Urothelial carcinoma (UCC), also known as transitional cell carcinoma (TCC) is a type of cancer that typically occurs in the urinary system. It is the most common type of bladder cancer and cancer of the ureter.
UCC is the second most common type of kidney cancer, but accounts for only five to 10% of all primary renal malignant tumors. UCC arises from the transitional epithelium, a tissue lining the inner surface of these hollow organs. Transitional cell carcinoma (TCC) accounts for more than 95% of urothelial tumors of the upper urinary tract.
Scientists at the University of Chicago (Chicago, IL, USA) searched their Department of Pathology archive for all cases of upper urothelial tract biopsies and washings between the years 2005 and 2015 that had nephroureterectomy for urothelial carcinoma. In all, 126 patients met the inclusion criteria. They considered cytology diagnoses of either urothelial cancer or “suspicious for urothelial cancer” to be positive. They compared the concordance between combined biopsy and washing, and then compared biopsy and washing diagnoses with the presence of carcinoma on resection.
The team found that from the 126 patients who had resection, only 72 patients had prior diagnostic material. Of those, 33 (26%) had combined biopsy and washing, 26 (21%) had biopsy only, and 13 (10%) had washing only. Among the patients who had had both procedures, 15 (45%) of the diagnoses were concordant as indicated by positive biopsy and cytology, and the final resection specimen revealed urothelial carcinoma. One patient, who was considered concordant, had negative results for both procedures but had urothelial carcinoma on resection.
The scientists found that among the 17 discordant combined biopsy and cytology cases, 11 had positive biopsy with negative washing, four had negative biopsy with positive washing and for two cases, neither biopsy nor washing was diagnostic. Among the 11 positive biopsies with negative washing, five were low-grade papillary urothelial cancer, four were high-grade papillary urothelial cancer, one was urothelial cancer in situ, and one was high-grade urothelial cancer suspicious for invasion.
Providers often obtain biopsies and cytology washings of the upper urinary tract to help them diagnose urothelial cancer, but may have only one procedure performed. Shiraz Fidai, MD, and Tatjana Antic, MD, co-authors of the study, said, “Overall, based on our data, both biopsies and washings of the upper tract (83% for biopsies and 59% for washings) are appropriate in diagnosing urothelial cancer. However, biopsies are more suitable for diagnosing low-grade papillary urothelial cancer when compared with cytology. Size and multifocality of the urothelial cancer of the upper urinary tract plays a significant role in obtaining an adequate specimen for either diagnosis or grading.” The study was presented at the Annual Meeting of the American Society for Clinical Pathology (ASCP), held September 6-8, 2017, in Chicago, IL, USA.
Related Links:
University of Chicago
UCC is the second most common type of kidney cancer, but accounts for only five to 10% of all primary renal malignant tumors. UCC arises from the transitional epithelium, a tissue lining the inner surface of these hollow organs. Transitional cell carcinoma (TCC) accounts for more than 95% of urothelial tumors of the upper urinary tract.
Scientists at the University of Chicago (Chicago, IL, USA) searched their Department of Pathology archive for all cases of upper urothelial tract biopsies and washings between the years 2005 and 2015 that had nephroureterectomy for urothelial carcinoma. In all, 126 patients met the inclusion criteria. They considered cytology diagnoses of either urothelial cancer or “suspicious for urothelial cancer” to be positive. They compared the concordance between combined biopsy and washing, and then compared biopsy and washing diagnoses with the presence of carcinoma on resection.
The team found that from the 126 patients who had resection, only 72 patients had prior diagnostic material. Of those, 33 (26%) had combined biopsy and washing, 26 (21%) had biopsy only, and 13 (10%) had washing only. Among the patients who had had both procedures, 15 (45%) of the diagnoses were concordant as indicated by positive biopsy and cytology, and the final resection specimen revealed urothelial carcinoma. One patient, who was considered concordant, had negative results for both procedures but had urothelial carcinoma on resection.
The scientists found that among the 17 discordant combined biopsy and cytology cases, 11 had positive biopsy with negative washing, four had negative biopsy with positive washing and for two cases, neither biopsy nor washing was diagnostic. Among the 11 positive biopsies with negative washing, five were low-grade papillary urothelial cancer, four were high-grade papillary urothelial cancer, one was urothelial cancer in situ, and one was high-grade urothelial cancer suspicious for invasion.
Providers often obtain biopsies and cytology washings of the upper urinary tract to help them diagnose urothelial cancer, but may have only one procedure performed. Shiraz Fidai, MD, and Tatjana Antic, MD, co-authors of the study, said, “Overall, based on our data, both biopsies and washings of the upper tract (83% for biopsies and 59% for washings) are appropriate in diagnosing urothelial cancer. However, biopsies are more suitable for diagnosing low-grade papillary urothelial cancer when compared with cytology. Size and multifocality of the urothelial cancer of the upper urinary tract plays a significant role in obtaining an adequate specimen for either diagnosis or grading.” The study was presented at the Annual Meeting of the American Society for Clinical Pathology (ASCP), held September 6-8, 2017, in Chicago, IL, USA.
Related Links:
University of Chicago
Latest Pathology News
- Advanced Imaging Reveals Mechanisms Causing Autoimmune Disease
- AI Model Effectively Predicts Patient Outcomes in Common Lung Cancer Type
- AI Model Predicts Patient Response to Bladder Cancer Treatment
- New Laser-Based Method to Accelerate Cancer Diagnosis
- New AI Model Predicts Gene Variants’ Effects on Specific Diseases
- Powerful AI Tool Diagnoses Coeliac Disease from Biopsy Images with Over 97% Accuracy
- Pre-Analytical Conditions Influence Cell-Free MicroRNA Stability in Blood Plasma Samples
- 3D Cell Culture System Could Revolutionize Cancer Diagnostics
- Painless Technique Measures Glucose Concentrations in Solution and Tissue Via Sound Waves
- Skin-Based Test to Improve Diagnosis of Rare, Debilitating Neurodegenerative Disease
- Serum Uromodulin Could Indicate Acute Kidney Injury in COVID-19 Patients
- AI Model Reveals True Biological Age From Five Drops of Blood
- First-Of-Its-Kind AI Tool Visualizes Cell’s ‘Social Network’ To Treat Cancer
- New Test Diagnoses High-Risk Childhood Brain Tumors
- Informatics Solution Elevates Laboratory Efficiency and Patient Care
- Microfluidic Device Assesses Stickiness of Tumor Cells to Predict Cancer Spread
Channels
Clinical Chemistry
view channel
Carbon Nanotubes Help Build Highly Accurate Sensors for Continuous Health Monitoring
Current sensors can measure various health indicators, such as blood glucose levels, in the body. However, there is a need to develop more accurate and sensitive sensor materials that can detect lower... Read more
Paper-Based Device Boosts HIV Test Accuracy from Dried Blood Samples
In regions where access to clinics for routine blood tests presents financial and logistical obstacles, HIV patients are increasingly able to collect and send a drop of blood using paper-based devices... Read moreMolecular Diagnostics
view channel
RNA-Based Blood Test Detects Preeclampsia Risk Months Before Symptoms
Preeclampsia remains a major cause of maternal morbidity and mortality, as well as preterm births. Despite current guidelines that aim to identify pregnant women at increased risk of preeclampsia using... Read more
First Of Its Kind Test Uses microRNAs to Predict Toxicity from Cancer Therapy
Many men with early-stage prostate cancer receive stereotactic body radiotherapy (SBRT), a highly precise form of radiation treatment that is completed in just five sessions. Compared to traditional radiation,... Read more
Novel Cell-Based Assay Provides Sensitive and Specific Autoantibody Detection in Demyelination
Anti-myelin-associated glycoprotein (MAG) antibodies serve as markers for an autoimmune demyelinating disorder that affects the peripheral nervous system, leading to sensory impairment. Anti-MAG-IgM antibodies... Read moreHematology
view channel
New Scoring System Predicts Risk of Developing Cancer from Common Blood Disorder
Clonal cytopenia of undetermined significance (CCUS) is a blood disorder commonly found in older adults, characterized by mutations in blood cells and a low blood count, but without any obvious cause or... Read more
Non-Invasive Prenatal Test for Fetal RhD Status Demonstrates 100% Accuracy
In the United States, approximately 15% of pregnant individuals are RhD-negative. However, in about 40% of these cases, the fetus is also RhD-negative, making the administration of RhoGAM unnecessary.... Read moreImmunology
view channel
Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer
Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more
Machine Learning-Enabled Blood Test Predicts Immunotherapy Response in Lymphoma Patients
Chimeric antigen receptor (CAR) T-cell therapy has emerged as one of the most promising recent developments in the treatment of blood cancers. However, over half of non-Hodgkin lymphoma (NHL) patients... Read moreMicrobiology
view channel
Handheld Device Deliver Low-Cost TB Results in Less Than One Hour
Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more
New AI-Based Method Improves Diagnosis of Drug-Resistant Infections
Drug-resistant infections, particularly those caused by deadly bacteria like tuberculosis and staphylococcus, are rapidly emerging as a global health emergency. These infections are more difficult to treat,... Read more
Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours
Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read moreTechnology
view channel
Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples
Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more
Innovative, Label-Free Ratiometric Fluorosensor Enables More Sensitive Viral RNA Detection
Viruses present a major global health risk, as demonstrated by recent pandemics, making early detection and identification essential for preventing new outbreaks. While traditional detection methods are... Read moreIndustry
view channel
Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions
Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Grifols and Tecan’s IBL Collaborate on Advanced Biomarker Panels
Grifols (Barcelona, Spain), one of the world’s leading producers of plasma-derived medicines and innovative diagnostic solutions, is expanding its offer in clinical diagnostics through a strategic partnership... Read more